|
1
|
Flattet Y, Garin N, Serratrice J, Perrier
A, Stirnemann J and Carballo S: Determining prognosis in acute
exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 12:467–475.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dixit D, Bridgeman MB, Andrews LB,
Narayanan N, Radbel J, Parikh A and Sunderram J: Acute
exacerbations of chronic obstructive pulmonary disease: Diagnosis,
management, and prevention in critically ill patients.
Pharmacotherapy. 35:631–648. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Sethi S: Infectious etiology of acute
exacerbations of chronic bronchitis. Chest. 117 (5 Suppl
2):380S–385S. 2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Holden V, Slack III D and McCurdy MT:
Diagnosis and management of acute exacerbations of chronic
obstructive pulmonary disease. Emerg Med Pract. 19:1–24.
2017.PubMed/NCBI
|
|
5
|
Hakamy A, McKeever TM, Steiner MC, Roberts
CM, Singh SJ and Bolton CE: The use of the practice walk test in
pulmonary rehabilitation program: National COPD audit pulmonary
rehabilitation workstream. Int J Chron Obstruct Pulmon Dis.
12:2681–2686. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Miravitlles M and Anzueto A: Role of
infection in exacerbations of chronic obstructive pulmonary
disease. Curr Opin Pulm Med. 21:278–283. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cazzola M, MacNee W, Martinez FJ, Rabe KF,
Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli
BR, et al: Outcomes for COPD pharmacological trials: From lung
function to biomarkers. Eur Respir J. 31:416–469. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Biomarkers Definitions Working Group.
Biomarkers and surrogate endpoints: Preferred definitions and
conceptual framework. Clin Pharmacol Ther. 69:89–95.
2001.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Miller M, Cho JY, Pham A, Ramsdell J and
Broide DH: Adiponectin and functional adiponectin receptor 1 are
expressed by airway epithelial cells in chronic obstructive
pulmonary disease. J Immunol. 182:684–691. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liu YJ, Du P and Rao J: Procalcitonin as a
diagnostic and prognostic marker for sepsis caused by intestinal
infection: A case report. Eur Rev Med Pharmacol Sci. 17:1311–1313.
2013.PubMed/NCBI
|
|
11
|
Irusen EM: Deciphering the new global
initiative for chronic obstructive lung disease (GOLD) guideline.
Curr Respir Care Rep. 1:183–188. 2012.
|
|
12
|
Müller B and Becker KL: Procalcitonin: How
a hormone became a marker and mediator of sepsis. Swiss Med Wkly.
131:595–602. 2001.PubMed/NCBI
|
|
13
|
Bohuon C: A brief history of
procalcitonin. Intensive Care Med. 26 (Suppl 2):S146–S147.
2008.
|
|
14
|
Fisher LA, Kikkawa DO, Rivier JE, Amara
SG, Evans RM, Rosenfeld MG, Vale WW and Brown MR: Stimulation of
noradrenergic sympathetic outflow by calcitonin gene-related
peptide. Nature. 305:534–536. 1983.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Snider RH Jr, Nylen ES and Becker KL:
Procalcitonin and its component peptides in systemic inflammation:
Immunochemical characterization. J Investig Med. 45:552–560.
1997.PubMed/NCBI
|
|
16
|
Julie D: Procalcitonin. J Clin Pathol.
68:675–679. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Gilbert DN: Procalcitonin as a biomarker
in respiratory tract infection. Clin Infect Dis. 52 (Suppl
4):S346–S350. 2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Park JH, Wee JH, Choi SP and Oh SH: The
value of procalcitonin level in community-acquired pneumonia in the
ED. Am J Emerg Med. 30:1248–1254. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Clyne B and Olshaker JS: The C-reactive
protein. J Emerg Med. 17:1019–1025. 1999.PubMed/NCBI View Article : Google Scholar
|
|
20
|
O'Donnell RA, Peebles C, Ward JA, Daraker
A, Angco G, Broberg P, Pierrou S, Lund J, Holgate ST, Davies DE, et
al: Relationship between peripheral airway dysfunction, airway
obstruction, and neutrophilic inflammation in COPD. Thorax.
59:837–842. 2004.PubMed/NCBI View Article : Google Scholar
|
